GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (FRA:RQE1) » Definitions » Tax Expense

ReNeuron Group (FRA:RQE1) Tax Expense : €-1.14 Mil (TTM As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is ReNeuron Group Tax Expense?

ReNeuron Group's tax expense for the months ended in Sep. 2023 was €-0.45 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.14 Mil.


ReNeuron Group Tax Expense Historical Data

The historical data trend for ReNeuron Group's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Tax Expense Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.37 -2.74 -2.40 -1.64 -1.42

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -0.76 -0.73 -0.69 -0.45

ReNeuron Group Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (FRA:RQE1) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


ReNeuron Group Tax Expense Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (FRA:RQE1) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

ReNeuron Group (FRA:RQE1) Headlines

No Headlines